Oral BMS-354825 rescues Gleevec-resistant CML

被引：0
|
作者：
不详
机构：
来源：
CANCER BIOLOGY & THERAPY | 2004年 / 3卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：700 / 700
页数：1
相关论文
共 50 条
  • [41] Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL
    Amrita V. Kamath
    Jian Wang
    Francis Y. Lee
    Punit H. Marathe
    Cancer Chemotherapy and Pharmacology, 2008, 61 : 365 - 376
  • [42] Dasatinib (SPRYCEL®, BMS-354825) phase-I/II study of patients with, chronic myeloid leukemia (CML) resistant or intolerant to imatinib:: Results of the CA180031 study in Japan (Phase I portion).
    Sakamaki, Hisashi
    Fujisawa, Shin
    Tobinai, Kensei
    Taniwaki, Masafumi
    Miyawaki, Shuichi
    Jinnai, Itsuro
    Utsunomiya, Atae
    Tanimoto, Mistune
    Morishima, Yasuo
    Okada, Masaya
    Miyazaki, Yasushi
    Uoshima, Nobuhiko
    Seriu, Taku
    BLOOD, 2006, 108 (11) : 287B - 287B
  • [43] Complete regression of cutaneous lesions of refractory Ph+ ALL after 4 weeks of treatment with BMS-354825
    Abruzzese, Elisabetta
    Del Poeta, Giovanni
    Barbato, Rosanna
    Fratoni, Stefano
    Trawinska, Malgorzata M.
    Zangrilli, Daniela
    Coletta, Angela M.
    Patroi, Ivona M.
    Francesconi, Francesca
    Santeusanio, Giuseppe
    De Fabritiis, Paolo
    Arnadori, Sergio
    BLOOD, 2006, 107 (11) : 4571 - 4572
  • [44] Dasatinib (BMS-354825) in patients with chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph plus ALL) who are resistant or intolerant to imatinib: Update of a phase I study.
    Sawyers, CL
    Kantarjian, H
    Shah, N
    Cortes, J
    Paquette, R
    Donato, N
    Nicoll, J
    Bleickardt, E
    Chen, TT
    Talpaz, M
    BLOOD, 2005, 106 (11) : 16A - 16A
  • [45] Dasatinib (BMS-354825) inhibits stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells
    Nam, Sangkil
    Lee, Francis
    Jove, Richard
    CANCER RESEARCH, 2006, 66 (08)
  • [46] Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells
    Nam, Sangkil
    Williams, Ann
    Vultur, Adina
    List, Alan
    Halla, Kapil
    Smith, David
    Lee, Francis Y.
    Jove, Richard
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (04) : 1400 - 1405
  • [47] Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism
    Zhang, H.
    Trachootham, D.
    Lu, W.
    Carew, J.
    Giles, F. J.
    Keating, M. J.
    Arlinghaus, R. B.
    Huang, P.
    LEUKEMIA, 2008, 22 (06) : 1191 - 1199
  • [48] Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis
    Shah, Neil P.
    Lee, Francis Y.
    Luo, Roger
    Jiang, Yibin
    Donker, Marjolein
    Akin, Cem
    BLOOD, 2006, 108 (01) : 286 - 291
  • [49] The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro
    Blake, Stephen
    Hughes, Timothy P.
    Mayrhofer, Graham
    Lyons, A. Bruce
    CLINICAL IMMUNOLOGY, 2008, 127 (03) : 330 - 339
  • [50] Correlation of clinical response to BMS-354825 with BCR-ABL mutation status in imatinill-resistant patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-associated acute lymphoblastic leukemia (Ph plus ALL).
    Shah, N
    Sawyers, CL
    Kantarjian, HMM
    Donato, N
    Nicoll, J
    Cortes, J
    Paquette, R
    Huang, F
    Clark, E
    Talpaz, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 565S - 565S
12345